On September 22, 2009, the 27th meeting held by the Central Epidemic Command Center (CECC) was convened by the Vice Premier of the Executive Yuan, Li-Luan Chu.As the pandemic influenza A (H1N1) vaccine has been the most important issue so far, Adimmune Corporation was invited to the meeting to report the progress on the vaccine. In addition, the evaluation of vaccine safety and the immunization plan were reported by the Department of Health at the meeting.

According to Adimmune Corporation, the production of the pandemic influenza A (H1N1) vaccine is being proceeded as scheduled. Around 130,000 embryonated chickens’ eggs were contained in each batch and 18 batches have been completed. According to the testing results showed, the quality of the vaccine conforms with the World Health Organization requirements. Human clincal trials will be conducted soon. The manager of Adimmune Corporation said that 60 additional participants will be included in the trial to determine the effect of one dose of vaccine. About 480 human participants have been tested so far.

Vice Premiere Chu indicated that the clinical trial should conform with the international ethics. He also pointed out that the Department of Health should ensure the vaccine safety and public confidence in the pandemic influenza A (H1N1) vaccine.